← ANALYSTS · TIPRANKS
Vamil Divan · Guggenheim
Hits
59%
289 of 489 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+13.5%
Over a year after the rating, TipRanks’ measure
Our companies rated now
14
Buy / hold / sell: 13 / 1 / 0
Upside of the analyst’s targets
+120.5%
Average over 14 current targets, to the last price
The market’s answer to the ratings
−3.1%
Day-0 move against SPY in the rating’s direction, average over 10 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 15on TipRanks Oct 16 07:30 | JBIOIWMJade Biosciences · $855M | Reiterated | Buy | $47.00 | +248.9% | +2.1%next day −1.0% | ↗ |
| Oct 12on TipRanks Oct 13 07:10 | AMGNQQQSPYAmgen · $235B | Reiterated | Hold | $388 → $378−2.6% | −12.6% | +0.7%next day −1.1% | ↗ |
| Oct 12on TipRanks Oct 13 07:10 | PFESPYPfizer · $168B | Reiterated | Buy | $31.00 | +4.8% | +0.5%next day −0.1% | ↗ |
| Oct 8on TipRanks Oct 9 08:50 | ABBVSPYAbbVie · $501B | Reiterated | Buy | $288 | +0.9% | +0.8%next day +0.9% · 5 days +4.9% | ↗ |
| Oct 6on TipRanks Oct 7 07:11 | JNJSPYJohnson & Johnson · $610B | Reiterated | Buy | $287 | +12.3% | +0.2%next day +1.7% · 5 days −2.3% | ↗ |
| Oct 6on TipRanks Oct 7 07:11 | TVTXIWMTravere Therapeutics · $5.0B | Reiterated | Buy | $89.00 | +79.4% | −3.5%next day −4.3% · 5 days −7.3% | ↗ |
| Oct 5on TipRanks Oct 6 10:10 | ANIPIWMANI Pharmaceuticals · $1.7B | Reiterated | Buy | $119 | +64.6% | −0.1%next day −2.0% · 5 days +1.0% | ↗ |
| Oct 1on TipRanks 11:50 | JBIOIWMJade Biosciences · $855M | Reiterated | Buy | $47.00 | +248.9% | −2.2%next day +1.8% · 5 days +1.5% | ↗ |
| Sep 23on TipRanks Sep 24 07:10 | TVTXIWMTravere Therapeutics · $5.0B | Reiterated | Buy | $75.00 → $89.00+18.7% | +79.4% | 0.0%next day +1.4% · 5 days −0.9% | ↗ |
| Sep 8on TipRanks 07:30 | MRKSPYMerck & Company · $358B | Reiterated | Buy | $146 → $170+16.4% | +16.5% | −0.7%next day −0.2% · 5 days −1.5% | ↗ |
| Aug 20on TipRanks Aug 21 06:50 | SVRAIWMSavara · $974M | Reiterated | Buy | $11.00 | +147.2% | −0.8%next day +1.4% · 5 days −1.1% | ↗ |
| Aug 16on TipRanks Aug 17 07:32 | ASMBIWMAssembly Biosciences · $419M | Reiterated | Buy | $43.00 | +114.0% | −8.4%next day +7.7% · 5 days +18.8% | ↗ |
| Aug 14on TipRanks Aug 17 07:32 | VERAIWMVera Therapeutics · $2.1B | Reiterated | Buy | $76.00 | +172.6% | +9.7%next day +0.5% · 5 days +3.4% | ↗ |
| Aug 12on TipRanks Aug 13 07:10 | UNCYIWMUnicycive Therapeutics · $100M | Reiterated | Buy | $37.00 → $25.00−32.4% | +644.0% | +7.5%next day −0.5% · 5 days +4.0% | ↗ |
| Aug 10on TipRanks Aug 11 07:10 | JBIOIWMJade Biosciences · $855M | Reiterated | Buy | $47.00 | +248.9% | −1.0%next day +3.2% · 5 days +8.0% | ↗ |
| Aug 7on TipRanks Aug 10 07:25 | ANIPIWMANI Pharmaceuticals · $1.7B | Reiterated | Buy | $124 → $119−4.0% | +64.6% | −5.9%next day −3.2% · 5 days −2.6% | ↗ |
| Aug 7on TipRanks Aug 10 07:25 | AMGNQQQSPYAmgen · $235B | Reiterated | Hold | $343 → $388+13.1% | −10.3% | +0.9%next day +1.6% · 5 days +0.6% | ↗ |
| Aug 6on TipRanks Aug 7 07:45 | PFESPYPfizer · $168B | Reiterated | Buy | $35.00 → $31.00−11.4% | +4.8% | +1.7%next day +1.5% · 5 days +1.1% | ↗ |
| Aug 6on TipRanks Aug 7 07:45 | INSMInsmed · $21.5B | Reiterated | Buy | $207 → $205−1.0% | +112.9% | +34.0%next day −1.7% · 5 days −5.9% | ↗ |
| Aug 5on TipRanks Aug 6 06:50 | JNJSPYJohnson & Johnson · $610B | Reiterated | Buy | $270 → $287+6.3% | +12.3% | +1.2%next day −0.1% · 5 days +0.9% | ↗ |
| Aug 3on TipRanks Aug 4 07:51 | ABBVSPYAbbVie · $501B | Reiterated | Buy | $261 → $288+10.3% | +0.9% | −3.8%next day −2.3% · 5 days −0.9% | ↗ |
| Jun 25on TipRanks 07:50 | ABSIIWMAbSci · $1.5B | Reiterated | Buy | $15.00 | +81.8% | +1.2%next day +7.4% · 5 days +12.4% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗